Compare
Lilly (Eli) vs Organon & (LLY vs OGN)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Lilly (Eli) (LLY) returned +46.2% and Organon & (OGN) +117.4%; so far this year the figures are +26.0% and +93.4%.
Lilly (Eli) is the larger company by market value, about 349.9 times the size of Organon &.
On trailing earnings, LLY trades at 43.9 times and OGN at 18.0 times.
Revenue grew +45.5% at LLY and -3.2% at OGN over the last year.
LLY yields 0.49%. OGN yields 0.58%.
Data as of the latest close. Not investment advice.
Relative performance
| LLY | OGN | |
|---|---|---|
| Price | $1,354.00 | $13.87 |
| 1-day | -0.79% | +0.58% |
| YTD | +25.99% | +93.44% |
| 1 year | +46.25% | +117.40% |
| 3 years | +144.20% | -5.32% |
| Market cap | $1.27T | $3.6B |
| P/E | 43.9 | 18.0 |
| P/S | 14.73 | 0.60 |
| P/B | 31.63 | 3.05 |
| Revenue growth | +45.50% | -3.20% |
| EPS growth | +50.70% | -59.70% |
| Gross margin % | 83.6 | 53.1 |
| Net margin % | 31.9 | 3.5 |
| ROE % | 68.5 | 17.9 |
| Debt / equity | 1.23 | 7.17 |
| FCF yield % | 2.4 | 18.5 |
| Dividend yield % | 0.49 | 0.58 |
| Beta | 0.29 | 0.68 |
| RSI (14) | 61.1 | 64.0 |
| Technical rating |